159nok
2,3 %
Date:2024-04-30Time:17:30:00Latest report:Q4-2023List:Oslo BorsTicker:PCIB
Market Cap:59 mnokEnterprise Value:18 mnokNet Sales:- mnokEarnings:-20,3 mnokEmployees:0ISIN:NO0010405640

Ratios

10-year key figure history for PCI Biotech turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PCI Biotech with index and moving average MA50 and MA200.

Stockprice:1,59
MA50:1,73
MA200:1,92
Price/MA200:-17,3 %
RSI (14):41,2
Price/MA50:-8,4 %

Description

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

Biotechnology